---
title: "Ersodetug (RZ358) in Tumor hyperinsulinism: Long-term morbidity"
description: "Formulary evidence on Ersodetug (RZ358) in Tumor hyperinsulinism: Long-term morbidity. Topics: Insulinoma: long-term morbidity compared with matched controls, Insulinoma: late surgical complications, Insulinoma: residual hypoglycemia and post-treatment diabetes in a Japanese nationwide survey, Insulinoma: neurological impairment and cognitive function, and 1 further topic. 5 evidence topics quoted from 5 sources."
canonical: "https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/product-information-and-disease-description/long-term-morbidity"
published: "2026-11-15T20:24:18-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Ersodetug (RZ358) in Tumor hyperinsulinism: Long-term morbidity

<a id="heading-2.2.1.7"></a>

## 2.2.1.7 Long-term Morbidity

<a id="topic-2.2.1.7-1"></a>

### Insulinoma: long-term morbidity compared with matched controls

> “The long-term incidence of atrial fibrillation (rate ratio (RR): 2.07 (95% CI: 1.02–4.22)), intestinal obstruction (18.65 (2.09–166.86)), and possibly breast (4.46 (1.29–15.39) and kidney cancers (RR not applicable) was increased among insulinoma patients vs controls, P < 0.05 for all comparisons.”
> “Endocrine disorders and pancreatic diseases were more frequent in the patients during the first year after insulinoma diagnosis, but not later on.”
> “The incidence of dementia or all mental and behavioural disorders did not significantly differ between the patients and the controls”

Source: [Peltola et al. (2021b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8784472/)

<a id="topic-2.2.1.7-2"></a>

### Insulinoma: late surgical complications

> “Most cases of pancreatitis occurred as early postoperative complications, with a rate of 10% in the surgically treated patients, as described previously”
> “Intestinal obstruction occurred in 5% of the surgically treated patients, likely as a late postoperative complication of insulinoma surgery.”

Source: [Peltola et al. (2021b)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8784472/)

<a id="topic-2.2.1.7-3"></a>

### Insulinoma: residual hypoglycemia and post-treatment diabetes in a Japanese nationwide survey

> “Post‐surgery residual hypoglycemia was found in eight patients: one had benign, five had malignant, and two had unknown histology.”
> “By contrast, post‐treatment diabetes mellitus was more prevalent and found in 25 (15.8%) patients who underwent pancreatectomy: 3.8% of those who had tumor enucleation, 21.3% of body and/or tail resection, 26.3% of pancreatoduodenectomy, and 100% of subtotal resection.”
> “In addition, impaired quality of life was often reported in patients with residual hypoglycemia (9/29), which included persistent hypoglycemia requiring frequent snacks causing obesity or frequent hypoglycemic loss of consciousness.”

Source: [Yamada et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7232294/)

<a id="topic-2.2.1.7-4"></a>

### Insulinoma: neurological impairment and cognitive function

> “Even after undergoing these extensive treatments, neurological impairment still occurred in 22 (10.7%) patients with insulinoma: seven had dementia, seven had epilepsy and eight had other neurological deficits.”

Source: [Yamada et al. (2020)](https://pmc.ncbi.nlm.nih.gov/articles/PMC7232294/)

> “Eighteen out of thirty-four patients (53%) with insulinoma were screened positive for cognitive impairment as defined by a MoCA score <26.”
> “The remaining ten patients with cognitive impairment showed improvements 1 year postoperatively, and seven patients recovered to normal cognitive function.”

Source: [Dai et al. (2019)](https://pubmed.ncbi.nlm.nih.gov/31292840/)

<a id="topic-2.2.1.7-5"></a>

### Malignant insulinoma: morbidity of refractory hypoglycemia

> “Refractory hypoglycemia is common in malignant insulin-secreting tumors and is associated with substantial morbidity.”

Source: [Strosberg et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13671785/)

<a id="topic-2.2.1.7-6"></a>

### NICTH: long-term morbidity

No evidence found.

Additional sources: [Kurakawa et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/34343300/)

## Related pages
- [Ersodetug (RZ358): Tumor hyperinsulinism](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism.md)
- [Ersodetug (RZ358) in Tumor hyperinsulinism: Terms and abbreviations](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/terms-and-abbreviations.md)
- [Ersodetug (RZ358): Tumor hyperinsulinism](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/executive-summary) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/executive-summary.md)
- [Ersodetug (RZ358) in Tumor hyperinsulinism: Product information and disease description](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/product-information-and-disease-description.md)
- [Ersodetug (RZ358) in Tumor hyperinsulinism: Clinical evidence](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/clinical-evidence.md)
- [Ersodetug (RZ358) in Tumor hyperinsulinism: Economic information and modeling report](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/economics) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/economics.md)
- [Ersodetug (RZ358) in Tumor hyperinsulinism: References](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/references) · [Markdown](https://www.evicenter.com/drugs/ersodetug--tumor-hyperinsulinism/references.md)
